Enhanced Eradication of Lymphoma by Tumor-Specific Cytotoxic T Cells Secreting and Engineered Tumor-Specific Immunotoxin

Abstract

In this project, we proposed to use tumor-specific T cells to produce an immunotoxin (IT) targeting tumor cells only when these T cells are specifically activated by the tumor. We use lentiviral vectors to modify tumor specific T cells with our immunotoxin. PEA based immunotoxins affect cell viability by ADP ribozilation of their elongation factor-2. To produce high titer of vector encoding the IT we generated a producer cell line resistant to PEA toxin. We have established stable cell lines of PEA- resistant producer cells. Using these stable cell lines, we have produced a high titer of IT-lentivirus preparation and transduced T cells with these vectors encoding the immunotoxin. We have characterized the transduced T cells to ensure that their phenotype and function was not impaired by the genetic modification and compared them to parental T cells. Finally, we have verified that transduced T cells produced the therapeutic immunotoxin that specifically kills our targeted tumor cells.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 01, 2009
Accession Number
ADA510142

Entities

People

  • Patricia Yotnda

Organizations

  • Baylor College of Medicine

Tags

DTIC Thesaurus Topics

  • Azo Compounds
  • B Lymphocytes
  • Biomedical Research
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Coding
  • Cytokines
  • Elongation
  • Genes
  • Genetic Engineering
  • Genetics
  • Lymphocytes
  • Neoplasms
  • Phenotypes
  • Proteins
  • T Lymphocytes

Fields of Study

  • Biology

Readers

  • Immunology
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech